Skip to main content

Table 4 Example of tabular reporting of patient characteristics [180].

From: Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration

  

Patients

  
 

All

CK-19mRNA +

CK-19mRNA -

 

Characteristic

Number

%

Number

%

Number

%

P

Patients enrolled

444

 

100

181

 

40.8

263

 

59.2

 

Age, years

          

   Median

 

54

  

54

  

55

  

   Range

 

26 to 78

  

26 to 74

  

30 to 78

 

0.752

Menopausal status

         

0.075

   Premenopausal

191

 

43

87

 

45.5

104

 

54.5

 

   Postmenopausal

253

 

57

94

 

37.2

159

 

62.8

 

Tumor size

         

0.648

   T1

157

 

35.4

61

 

38.9

96

 

61.1

 

   T2

251

 

56.5

103

 

41

148

 

59

 

   T3

36

 

8.1

17

 

47.2

19

 

52.8

 

Histology grade

         

0.316

   I/II

204

 

46

87

 

42.6

117

 

57.4

 

   III

191

 

43

72

 

37.7

119

 

62.3

 

   Unknown

49

 

11

22

  

27

   

Infiltrated axillary lymph nodes

         

0.538

   0

163

 

36.7

61

 

37.4

102

 

62.6

 

   1 to 3

122

 

27.5

53

 

43.5

69

 

56.5

 

   ≥4

159

 

35.8

67

 

42.1

92

 

57.9

 

ER

         

0.779

   Negative

175

 

39.4

71

 

40.6

104

 

59.4

 

   Positive

260

 

58.6

109

 

41.9

151

 

58.1

 

   Unknown

9

 

2

1

  

8

   

PR

         

0.126

   Negative

234

 

52.7

89

 

38

145

 

62

 

   Positive

201

 

45.3

91

 

45.3

110

 

54.7

 

   Unknown

9

 

2

1

  

8

   

HER2

         

0.897

   0, 1+

290

 

65.3

122

 

42.1

168

 

57.9

 

   2+

53

 

11.9

21

 

39.6

32

 

60.4

 

   3+ by IHC

88

 

19.8

35

 

39.8

53

 

60.2

 

   Unknown

13

 

3

3

  

10

   

Adjuvant chemotherapy

         

0.425

   CMF

43

 

9.7

14

 

32.6

29

 

67.4

 

   FEC

209

 

47.1

84

 

40.2

125

 

59.8

 

   EC-T

192

 

43.2

83

 

43.2

109

 

56.8

 

Surgery

         

0.478

   L

310

 

69.8

123

 

39.7

187

 

60.3

 

   M

134

 

30.2

58

 

43.3

76

 

56.7

 

Radiotherapy

         

0.799

   No

81

 

18.2

32

 

39.5

49

 

60.5

 

   Yes

363

 

81.8

149

 

41

214

 

59

 
  1. CK-19: cytokeratin-19; CMF: cyclophosphamide, methotrexate, fluorouracil; EC-T: epirubicin, cyclophosphamide, docetaxel; ER: estrogen receptor; FEC: fluorouracil, epirubicin, cyclophosphamide; IHC: immunohistochemistry; L: lumpectomy; M: mastectomy; PR: progesterone receptor.